Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 5/20 | 0.54 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.54 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | SIK1 | P57059 | 1/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.35 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049498 | 0.85 | SCN2A (0.51) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| SCHEMBL7280704 | 0.82 | SCN2A (0.49) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| SCHEMBL168973 | 0.80 | SCN2A (0.57) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| SCHEMBL30413525 | 0.80 | SCN2A (0.57) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| SCHEMBL6049521 | 0.77 | SCN2A (0.54) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| SCHEMBL6049588 | 0.76 | SCN2A (0.43) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| SCHEMBL7278590 | 0.73 | SCN2A (0.51) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| SCHEMBL15914195 | 0.71 | SCN2A (0.49) | SCN2AKCNK2SCN10ASCN9ASCN3A | |
| Sipatrigine SCHEMBL135888 | 0.70 | SCN2A (1.00) | SCN2AKCNK2PTPN11 | |
| Sipatrigine SCHEMBL29421474 | 0.70 | SCN2A (1.00) | SCN2AKCNK2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5587380-A | ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. (US) | 1996-12-24 | — | — | US | claimed |
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-1325916-A1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | THE WELLCOME FOUNDATION LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| US-5712276-A | TREATING NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1998-01-27 | — | — | US | disclosed |
| US-5684005-A | PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE | GLAXO WELLCOME INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5635507-A | PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER | GLAXO WELLCOME INC. (US) | 1997-06-03 | — | — | US | disclosed |
| US-5597827-A | CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. | 1997-01-28 | — | — | US | disclosed |
| US-5597828-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY | GLAXO WELLCOME INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5591746-A | GLUTAMATE INHIBITORS; CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. | 1997-01-07 | — | — | US | disclosed |
| US-5587380-A | ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0727214-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0727213-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0727212-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| CN-1117046-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-02-21 | — | — | CN | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |